Medicago Reports Interim Results of Phase 1 COVID-19 Trial The Canadian Press ·
Canadian drug developer Medicago said Tuesday it has received promising early test results for its plant-derived vaccine for COVID-19.
The Quebec City-based company said interim results of a Phase 1 clinical trial found all subjects developed "a promising antibody response after two doses" of its COVID-19 vaccine candidate.
Phase 1 clinical trials include about 100 volunteers and are designed to flag any immediate safety concerns and offer an initial indication of whether the shots produce an immune response.
Medicago did not disclose full safety data and said the side effects were generally mild to moderate and short in duration. The company posted the results on a preprint server and still need to be
peer reviewed by independent experts to check its validity.
The
Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people aged 18-55.
Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its
plant-based COVID-19 vaccine candidate, subject to regulatory approval.
https://www.cbc.ca/news/health/medicago-covid-19-vaccine-phase-1-1.5796411